Boiron (FRA:BON) Debt-to-Revenue : 0.03 (As of Dec. 2023)

View and export this data going back to . Start your Free Trial

What is Boiron Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

Boiron's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €7.1 Mil. Boiron's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was €6.6 Mil. Boiron's annualized Revenue for the quarter that ended in Dec. 2023 was €506.7 Mil. Boiron's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.03.

Boiron Debt-to-Revenue Historical Data

The historical data trend for Boiron's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Boiron Debt-to-Revenue Chart

Boiron Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Revenue

Get a 7-Day Free Trial

0.02

0.03

0.04

0.03

Boiron Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Debt-to-Revenue	Get a 7-Day Free Trial															0.02	0.05	0.04	0.03	0.03

Competitive Comparison of Boiron's Debt-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Boiron's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Boiron's Debt-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Boiron's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where Boiron's Debt-to-Revenue falls into.

Boiron Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

Boiron's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(7.057	+	6.645)	/	493.248
	=	0.03

Boiron's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue	=	Total Debt			/	Revenue
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Revenue
	=	(7.057	+	6.645)	/	506.726
	=	0.03

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2023) Revenue data.

Boiron Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of Boiron's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Boiron (FRA:BON) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Boiron SA (FRA:BON) » Definitions » Debt-to-Revenue

Comparable Companies

Traded in Other Exchanges

BOIRF:USA BOI:France BON:Germany

Address

2, Avenue de l’Ouest Lyonnais No. 039, Messimy, FRA, 69510

Website

http://www.boiron.com

Boiron is a drug manufacturer that focuses on homeopathic products. The company's revenue is roughly split between its nonproprietary homeopathic medicines and products in its over-the-counter specialties category. Boiron's nonproprietary medicines are generic products that do not refer to any therapeutic indication, while the specialties category includes first-resort products provided in tablet form, are bottled to use as drops, syrups, or ointments. Geographical segments are France, Europe, North America, and other countries. It generates a majority of revenue from France. The company's products include Oscillococcinum, Stodal and Stodaline, Arnigel, Camilia, Sedatif PC, Coryzalia, Homeoptic, and Homeovox.